Tuesday, January 29, 2013

Vertex hepatitis C drug revenues plummet

Investment Commentary

Vertex hepatitis C drug revenues plummet

Galen Moore
Web Editor- Boston Business Journal

Vertex Pharmaceuticals (Nasdaq: VRTX) saw sales of its hepatitis C drug, Incivek, drop off precipitously in the fourth quarter, year over year. The fast decline in Incivek sales, less than two years after its U.S. Food and Drug Administration approval in May of 2011, underscores the fast-moving competitive landscape for hepatitis C. 
Cambridge, Mass.-based Vertex and several other competitors are locked in battle to try to come up with an all-oral drug cocktail that would eliminate the need for interferon injections, which would improve patients’ quality of life. In the meantime, some patients are putting off treatment or joining clinical trials rather than starting Incivek or other already-approved medicines.
Continue Reading....

Of Interest
Chronic Hepatitis C Infection: Treat Now or Wait?
A collection of articles weighing the risks and benefits of treating HCV now or waiting for future therapies

No comments:

Post a Comment